Weight Loss
LEAN
Physician-guided weight loss powered by GLP-1 peptide therapy. Tirzepatide and Semaglutide options.
What's in it
Tirzepatide
Dual GIP/GLP-1 receptor agonist
· FDA-approved for chronic weight management · Reduces appetite and slows gastric emptying · Improves insulin sensitivity · Titrated weekly subcutaneous injection
Shop this productSemaglutide
GLP-1 receptor agonist
· FDA-approved for weight management · Regulates appetite and blood sugar · Mimics natural incretin hormone · Titrated weekly subcutaneous injection
Shop this productLEAN uses GLP-1 receptor agonist therapy to help regulate appetite signals and metabolic function. Your prescribing provider selects Tirzepatide or Semaglutide based on your clinical profile, medical history, and goals.
Dosing begins low and titrates upward under clinical guidance. You will have regular check-ins with your provider to monitor progress, adjust dosing, and manage any side effects. Most patients begin to notice appetite changes within the first two weeks.
- Adults with a BMI of 27+ seeking clinically guided weight management
- Individuals who have tried diet and exercise alone without sustained results
- Patients preparing for surgery who need to optimize body composition
- People looking for a physician-supervised alternative to over-the-counter weight loss products
Tirzepatide (Mounjaro/Zepbound) and Semaglutide (Wegovy/Ozempic) are FDA-approved for chronic weight management. Clinical trials demonstrated average weight loss of 15-22% of body weight over 72 weeks with Tirzepatide and 12-17% with Semaglutide.
Reduced appetite and cravings
Most patients report a significant decrease in hunger and food-seeking behavior within the first 2-4 weeks.
Steady, sustainable weight loss
Clinical data supports progressive weight reduction when combined with lifestyle modifications.
Improved metabolic markers
Patients may see improvements in blood sugar, cholesterol, and blood pressure levels.
Increased energy
Some patients report improved energy levels as metabolic health improves.
- Licensed provider consultation and prescription
- Medication shipped directly to your door
- Dosing titration guidance and adjustment
- Regular provider check-ins
- Secure messaging with your care team
- Ongoing clinical monitoring
What is the difference between Tirzepatide and Semaglutide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, while Semaglutide targets only GLP-1 receptors. Both are FDA-approved for weight management. Your provider will recommend the best option for your clinical profile.
How quickly will I see results?
Most patients notice appetite changes within 2 weeks and measurable weight loss within 4-8 weeks. Individual results vary based on adherence, lifestyle, and starting weight.
Are there common side effects?
The most common side effects are mild nausea, constipation, or diarrhea, especially during the titration period. These typically improve as your body adjusts to the medication.
Do I need to follow a special diet?
No specific diet is required, but your provider may recommend nutritional guidelines to maximize results and support overall health.
Can I stop the medication once I reach my goal weight?
Your provider will work with you on a plan for maintenance. Discontinuation should always be done under clinical guidance.
Is this covered by insurance?
Truthe protocols are cash-pay and not billed to insurance. However, you may be able to use FSA/HSA funds. Check with your plan administrator.
How is the medication administered?
Both Tirzepatide and Semaglutide are administered as a once-weekly subcutaneous injection using a pre-filled pen or syringe. Your provider will walk you through the injection process.